Related references
Note: Only part of the references are listed.Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus
Ippei Kanazawa et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Rosiglitazone-associated fractures in type 2 diabetes - An analysis from a diabetes outcome progression trial (ADOPT)
Steven E. Kahn et al.
DIABETES CARE (2008)
Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone
Oxana P. Lazarenko et al.
ENDOCRINOLOGY (2007)
The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women:: A randomized, controlled trial
Andrew Grey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2006)
Thiazolidinedione use and bone loss in older diabetic adults
Ann V. Schwartz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Adiponectin:: a relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity?
M Bouskila et al.
INTERNATIONAL JOURNAL OF OBESITY (2005)
Glycemic control from 1988 to 2000 among U.S adults diagnosed with type 2 diabetes - A preliminary report
CE Koro et al.
DIABETES CARE (2004)
Clinical use of thiazolidinediones: Recommendations
MJ Abrahamson
AMERICAN JOURNAL OF MEDICINE (2003)
Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control
V Fonseca et al.
DIABETES CARE (2003)
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes
TA Jones et al.
DIABETES OBESITY & METABOLISM (2003)
Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome
DH Akbar
ENDOCRINE (2003)
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus
SM Haffner et al.
CIRCULATION (2002)
Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients
WS Yang et al.
DIABETES CARE (2002)
Oral antihyperglycemic therapy for type 2 diabetes - Scientific review
SE Inzucchi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia
C Weyer et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
